NCT05017168View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

November 12, 2021

Study Completion Date

January 25, 2022

Conditions

SARS-CoV-2 Infection

Interventions

DRUG

CT-P63

CT-P63 will be administered

DRUG

Placebo

Placebo-matching CT-P63

Trial Locations (1)

05-410

Biokinetica S.A, Józefów

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celltrion

INDUSTRY